Zobrazeno 1 - 10
of 27
pro vyhledávání: '"G. skailes"'
Autor:
Goss G, Stan B. Kaye, Pledge S, Craig M. Williams, Hani Gabra, Paul Vasey, L.-A. Lewsley, Susana Banerjee, Marcia Hall, E. Gilby, G. J. S. Rustin, Michael A. Hogg, A. hindley, Peter Harper, Emma Kipps, A. Lamont, G. skailes, James Paul
Publikováno v:
Annals of Oncology. 24:679-687
Background: The aim of the study is to demonstrate that intrapatient dose escalation of carboplatin would improve the outcome in ovarian cancer compared with flat dosing. Patient and method: Patients with untreated stage IC-IV ovarian cancer received
Publikováno v:
Lung Cancer. 91:S56-S57
Autor:
K. Varadarajan, W. Appel, P. Bezecny, A. Hindley, G. Skailes, C. Benn, S. Lau, C. Abbott, H. Lee, M. Sivaramalingam
Publikováno v:
Lung Cancer. 87:S54
Autor:
David Ferry, C Lewanski, P Wells, B. Crosse, Marianne Nicolson, Manish Kumar, D. Dunlop, Penella J. Woll, J Thompson, Kenneth J. O'Byrne, A Chetiyawardana, H W Jarrett, R Shah, L J Billingham, G Skailes, P Leonard
Publikováno v:
Thorax. 66:A41-A42
Background Chemotherapy agents have dose-related effectiveness. The BTOG2 trial is a large phase III trial supported by the British Thoracic Oncology Group patients addressing this issue in which advanced non-small cell lung cancer were randomised to
Publikováno v:
Clinical oncology (Royal College of Radiologists (Great Britain)). 10(6)
Adenocarcinoma of the rete testis is a rare testicular tumour, which often presents late, with metastatic disease present in a significant proportion of patients. We record the clinicopathological findings in a man who presented with an apparently lo
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Clinical Oncology. 24:156
Autor:
P. Mulvenna, Clive Peedell, J. Hicks, Rhona McMenemin, G. Skailes, Nazia Mohammed, W. Appel, J. Maguire, V. Kelly
Publikováno v:
Lung Cancer. 75:S45
Autor:
Marianne Nicolson, David Ferry, L J Billingham, P Leonard, Manish Kumar, G Skailes, H W Jarrett, C Lewanski, J Thompson, A Chetiyawardana, M Hill, Penella J. Woll, D. Dunlop, P Wells, B. Crosse, Kenneth J. O'Byrne, P. Gaunt, R Shah
Publikováno v:
Thorax. 66:A41-A41
Background The standard of care for advanced NSCLC is platinum-based chemotherapy but the optimal dose of cisplatin and comparison with carboplatin is uncertain. With median survival at 8–12 months, the impact of such treatment choices on patients9
Autor:
Kenneth J. O'Byrne, David Ferry, M Hill, S Pirrie, B. Crosse, C Lewanski, H W Jarrett, A Chetiyawardana, P Wells, Manish Kumar, Marianne Nicolson, J Thompson, R Shah, G Skailes, Penella J. Woll, D. Dunlop, L J Billingham, P Leonard
Publikováno v:
Thorax. 66:A41-A41
Background Platins are considered key drugs in treating advanced NSCLC. Carboplatin has been reported as inferior to cisplatin in meta-analyses while the optimal dose of cisplatin is unclear. Methods Eligibility was by histologically proven NSCLC, PS